AstraZeneca Pharma India Limited (ASTRAZEN.NS)

INR 6482.05

(-0.0%)

Market Cap (In INR)

162.05 Billion

Revenue (In INR)

12.95 Billion

Net Income (In INR)

1.61 Billion

Avg. Volume

61.73 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4650.0-8139.0
PE
-
EPS
-
Beta Value
0.289
ISIN
INE203A01020
CUSIP
Y0431U139
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Sanjeev Kumar Panchal
Employee Count
-
Website
https://www.astrazeneca.in
Ipo Date
2002-07-01
Details
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.